临床局限性尿路上皮癌的分子亚型分型显示管腔型肿瘤在根治性膀胱切除术中病理升级率较低
本研究对206例接受根治性膀胱切除术(未行新辅助化疗)的高级别cT1-T2N0M0尿路上皮癌患者的膀胱切除前经尿道标本进行基因组亚型分类器(GSC)检测,发现管腔型肿瘤较非管腔型肿瘤病理升级至非器官局限性疾病的比例更低(34% vs 51%,p=0.02),差异局限于T分期,淋巴结阳性率无差异。多变量分析显示非管腔型患者升级至≥pT3的风险更高(p<0.001)。作者认为若经验证,这些数据有助于判断哪些患者可能需要多模式治疗。
要点
- cT1期病理升级率23%,cT2期57%。
- 管腔型 vs 非管腔型升级至非器官局限性疾病:34% vs 51%(p=0.02)。
- 多变量分析中非管腔型患者升级至≥pT3的风险更高(p<0.001)。
核心结论
- 临床局限性尿路上皮癌的分子亚型分型显示,管腔型肿瘤较非管腔型肿瘤升级至非器官局限性疾病的比例更低。
- 若经验证,这些数据有助于判断哪些患者可能需要多模式治疗。
研究设计与样本
- 多机构队列研究,纳入206例高级别、cT1-T2、N0M0尿路上皮癌患者,均接受根治性膀胱切除术且未行新辅助化疗,对膀胱切除前经尿道标本进行基因组亚型分类器(GSC)检测。
- 采用单变量和多变量逻辑回归分析评估GSC与病理升级(定义为根治性膀胱切除术时pT3/T4和/或pTanyN1-3)的关联。
主要发现
- 病理升级发生于23%的cT1病例和57%的cT2病例。
- 管腔型肿瘤较非管腔型肿瘤升级至非器官局限性疾病的比例更低(34% vs 51%,p=0.02)。
- 升级差异局限于T分期,管腔型与非管腔型患者淋巴结阳性率无差异(cT1:两组均为13%[p>0.9];cT2:分别为15%和23%[p=0.6])。
- 管腔型肿瘤患者升级至≥pT3Nany的比例低于非管腔型肿瘤(Mantel-Haenszel p=0.002;cT1:13% vs 30%;cT2:34% vs 58%)。
- 多变量逻辑回归分析中,非管腔型患者根治性膀胱切除术时升级至≥pT3的可能性更高(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性设计和样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Upstaging of clinical T1-T2 urothelial carcinoma (UC) to non-organ-confined (NOC) pathological stage ≥T3 or N+ at radical cystectomy (RC) is common. Tools for stratifying patients who may have NOC disease are limited. OBJECTIVE: To determine an association of a genomic subtyping classifier (GSC) with pathological upstaging in multi-institutional cohort of patients with cT1-T2 UC treated with RC. DESIGN, SETTING, AND PARTICIPANTS: Precystectomy transurethral specimens from 206 patients with high-grade, cT1-T2, N0M0 UC, who underwent RC without neoadjuvant chemotherapy, underwent GSC testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Uni- and multivariable logistic regression analyses evaluated GSC for upstaging, defined as pT3/T4 and/or pTanyN1-3 disease at RC. RESULTS AND LIMITATIONS: Pathological upstaging occurred in 23% of cT1 and 57% of cT2 cases. Lower rates of upstaging to NOC was seen for luminal versus nonluminal tumors (34% vs 51%, p=0.02). The differences in upstaging were confined to T stage, with no difference in node positivity for luminal versus nonluminal patients (cT1: 13% for both [p>0.9], cT2: 15% and 23% [p=0.6], respectively). Fewer patients with luminal tumors were upstaged to ≥pT3Nany compared with nonluminal tumors (Mantel-Haenszel p=0.002; cT1: 13% vs 30%, cT2: 34% vs 58%). On multivariable logistic regression analysis, nonluminal patients were more likely to be upstaged to ≥pT3 at RC (p<0.001). Limitations include retrospective design and sample size. CONCLUSIONS: Molecular subtyping of clinically localized UC demonstrated that luminal tumors have lower rates of upstaging to non-organ-confined disease compared with nonluminal tumors. If validated, these data can help inform which patients may need multimodal therapy. PATIENT SUMMARY: Determining whether bladder cancer has spread beyond the bladder is challenging at diagnosis. In this paper, genomics helped identify patients who were more likely to have aggressive disease that has spread outside the bladder. These patients may benefit from chemotherapy prior to surgery.
引用
- Lotan Y, Boorjian SA, Zhang J, et al. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019. PMID: 31092337. doi:10.1016/j.eururo.2019.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。